Sutro Biopharma, Inc.

STRONASDAQHealthcare● Active

$25.95

+$0.54(+2.13%)

Market Cap$251124793

P/E Ratio—

52W High$43.85

52W Low$6.7

Avg Volume268K

Open$26.04

Beta1.55

Overview

Sutro Biopharma, Inc. (STRO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

STRO · net income · updated Jun 9, 2026

Core profitability metrics

STRO · net income · margin · TTM · CAGR

Net income was −$191.1M for FY2025 (fiscal year ending 2025-12-31), up 16.0% year-over-year. Net profit margin was -186.4%. Based on available data, Sutro Biopharma, Inc. has been profitable since at least 2016.

FY2025 Net Income−$191.1M▲ +16.0% YoY

Trailing 12M (TTM)−$153.6Mtrailing 4 quarters sum

Net Profit Margin-186.4%−$191.1M ÷ $102.5M

YoY Change+16.0%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2016

▸ FMP /income-statement · Annual · STRO net income history · STRO profit margin

Annual net income data

STRO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$191.1M▲ +16.0%-186.4%$102.5M

FY2024Loss−$227.5M▼ 113.0%-366.6%$62.0M

FY2023Loss−$106.8M▲ +10.4%-69.5%$153.7M

FY2022Loss−$119.2M▼ 12.9%-175.9%$67.8M

FY2021Loss−$105.5M▼ 228.5%-170.6%$61.9M

Net income vs peers (Healthcare)

STRO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Sutro Biopharma, Inc.YOU

STRO

−$191.1M+16.0%-186.4%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Sutro Biopharma, Inc. (STRO) reported net income of −$191.1M for FY2025 (fiscal year ending 2025-12-31), up 16.0% year-over-year. The net profit margin was -186.4% — meaning the company kept $-1.86 of every dollar of revenue as profit.

Based on available data, Sutro Biopharma, Inc. has been profitable since at least 2016. Net income reached a peak of $1.7M in FY2016. Data available for 10 fiscal years.

Sutro Biopharma, Inc.'s net profit margin was -186.4% for FY2025, based on the latest annual results.

Investors sometimes search for "Sutro Biopharma, Inc. net worth" — the company's market capitalization is a separate figure from STRO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

STRO net income · 4 questions

Sutro Biopharma, Inc. is not currently profitable on an annual basis. The company reported a net loss of $191.1M for FY2025.

is STRO profitabledoes STRO make a profitSTRO profitabilitySTRO profitable company

▸ Source: FMP /income-statement · GAAP · Sutro Biopharma, Inc. · Sutro Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026